Hepatotoxicity of Rifampin and Pyrazinamide in the Treatment of Latent Tuberculosis Infection in HIV-Infected Persons: Is It Different Than in HIV-Uninfected Persons? | Zendy

Fred M. Gordin | Zendy; David L. Cohn | Zendy; John P. Matts | Zendy; Richard E. Chaisson | Zendy; R. J. O. Brien | Zendy

Open Access

Hepatotoxicity of Rifampin and Pyrazinamide in the Treatment of Latent Tuberculosis Infection in HIV-Infected Persons: Is It Different Than in HIV-Uninfected Persons?

Author(s) -

Fred M. Gordin,

David L. Cohn,

John P. Matts,

Richard E. Chaisson,

R. J. O. Brien

Publication year - 2004

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/422724

Subject(s) - medicine , pyrazinamide , bilirubin , latent tuberculosis , tuberculosis , gastroenterology , isoniazid , population , regimen , immunology , mycobacterium tuberculosis , pathology , environmental health

In 2000, results of a multinational trial demonstrated that a 2-month course of rifampin and pyrazinamide (RZ) was as effective as isoniazid (INH) in reducing tuberculosis in human immunodeficiency virus (HIV)-infected individuals with latent tuberculosis infection (LTBI). After the release of new guidelines, the Centers for Disease Control and Prevention received reports of severe hepatotoxicity associated with the use of the RZ regimen for the treatment of LTBI in the general population. To better understand the occurrence of hepatotoxicity in an HIV-infected population, we conducted a more detailed analysis of the liver function test results obtained in the multinational trial of RZ.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research